Jan. 12 Quick Takes: $230M series B for Flagship’s ‘gene writer’ Tessera; plus Elucida, Vedanta, AbbVie-Dragonfly, Primmune

By Jeff Cranmer, Executive Editor

Jan 13, 2021 | 1:58 AM GMT

Flagship Pioneering Gene Writing company Tessera Therapeutics Inc. raised a $230